Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01083849 · FLOW

Participant flow

Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice · Source last updated 2014-12-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and who were not yet on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
    id
    FG000
    title
    Paricalcitol Pre-dialysis Group
  2. description
    Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
    id
    FG001
    title
    Paricalcitol Dialysis Group
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        121
      2. group Id
        FG001
        num Subjects
        638
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        61
      2. group Id
        FG001
        num Subjects
        527
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        60
      2. group Id
        FG001
        num Subjects
        111
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
761 participants were enrolled in the study, but two participants lacked information necessary for assignment to one of the analysis groups (pre-dialysis or dialysis). Hence, analysis was conducted with 759 participants.
Complete source fields
groups
  1. description
    Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and who were not yet on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
    id
    FG000
    title
    Paricalcitol Pre-dialysis Group
  2. description
    Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
    id
    FG001
    title
    Paricalcitol Dialysis Group
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        121
      2. group Id
        FG001
        num Subjects
        638
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        61
      2. group Id
        FG001
        num Subjects
        527
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        60
      2. group Id
        FG001
        num Subjects
        111
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
761 participants were enrolled in the study, but two participants lacked information necessary for assignment to one of the analysis groups (pre-dialysis or dialysis). Hence, analysis was conducted with 759 participants.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice